MK-4334

DRUG2 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

Alzheimer's DiseaseCognitive Impairment Associated With SchizophreniaMild Cognitive Impairment

Phase 1

Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005)

WithdrawnNCT03740178

Merck Sharp & Dohme LLCAlzheimer's Disease, Mild Cognitive Impairment

Start: 2019-09-27End: 2020-02-28Updated: 2025-04-25

Evoked Responses as Pharmacodynamic Biomarkers in Healthy and Schizophrenic Participants (MK-4334-007)

CompletedNCT05136690

Merck Sharp & Dohme LLCCognitive Impairment Associated With Schizophrenia

Start: 2022-04-27End: 2022-11-04Updated: 2024-11-29